This a very clear article detailing a clinical trial rolling out the p-tau217 blood test in UK memory clinics. The article is easy to understand and summarises the point of the trial and potential benefits for Alzheimer's disease diagnosis very well. Slight criticisms would be a failure to mention some of the potential challenges in expanding this blood test to an NHS wide diagnostic test and to put this blood test in the context of the new Alzheimer's treatments that have recently been developed (how earlier diagnosis could lead to more effective treatment - although none of the new amyloid based Alzheimer's treatments are currently available on the NHS)

The article is well written and covers plenty of valid arguments against the amyloid hypothesis and shines a light on the weaknesses of the new amyloid clearing drugs that have recently been approved to treat Alzheimer's. However it must be said that there aren't many counter arguments presented. There is a very large body of evidence in favour of the amyloid hypothesis that isn't covered here. The article focuses quite heavily on the 2006 research article which falsified results linking aβ*56 to Alzheimer's disease (perhaps understandingly given the author broke the original story) but no mention is made of other amyloids that are also linked to Alzheimer's disease. I also think describing the field as a "mafia" is incorrect as many leading proponents of the amyloid hypothesis admit that other factors also contribute towards Alzheimer's (see Sir Professor John Hardy's comments in: https://www.alzheimers.org.uk/for-researchers/explaining-amyloid-research-study-controversy)

This article is relatively clear and provides evidence and quotes from several sources bemoaning the fact that Donanemab will not be available on the NHS. I would however question the balance of the article, which contains no sources backing the move and provides little background as to why this drug won't be available besides it being "too expensive".